Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain:...

Area of Science:

• Hematology
• Oncology
• Clinical Practice

Background:

• The treatment landscape for multiple myeloma (MM) is rapidly evolving.
• There is a need for real-world evidence on current MM management strategies.
• Managing newly diagnosed and relapsed/refractory (R/R) MM presents increasing complexity.

Purpose of the Study:

• To describe current clinical practices in multiple myeloma management.
• To gather insights from hematologists' experiences in Spain.
• To provide real-world data in the context of emerging therapies and limited existing guidelines.

Main Methods:

• A descriptive study utilizing aggregated data.
• Involved 23 hematologists from the Spanish public health system.
• Data collected via a 57-question survey on MM patient management.

Main Results:

• For ASCT-eligible patients, common induction therapies included daratumumab, bortezomib, lenalidomide, and dexamethasone (49.6%).
• Nearly all patients (97.8%) received maintenance therapy post-ASCT, primarily lenalidomide.
• For ASCT-ineligible patients, daratumumab, lenalidomide, and dexamethasone (66.1%) was the most frequent first-line treatment.

Conclusions:

• The study provides an overview of current real-world MM management in Spain.
• Highlights the adoption of novel therapies in clinical practice.
• Addresses the scarcity of current data and evolving treatment guidelines for MM.